Prathima is passionate about development and access of medicines to patients globally, and has stayed committed to this effort starting with her education (in pharmacy and PhD in protein chemistry) and her drug development career that spans over twenty years with experience in CMC for biologics (PoC, development/manufacturing) leading to IND/BLA filings.
Dr. Prathima Acharya M Pharm., PhD
and solving pain points in the biotech industry. One example being when she identified the potential of RPLs as capture resins for highly glycosylated molecules such as HIV gp120 envelope proteins and was instrumental in establishing an alliance with KBI Biopharma to establish PoC with their development teams. This work was presented at the HIV envelope workshop conducted by the NIH, Rockville, MD, USA (2nd Env Manufacturing Workshop, Sep 15, 2016) and the work is on-going.
Previously, Prathima was a key strategic member of the executive team at KBI Biopharma and under her leadership as the Chief Scientific Officer and Chief Business Development officer, the BD team achieved a four-fold increase in total annual signed proposals representing a 57% CAGR during this period. Prathima’s previous roles include senior positions at Schering Plough/Diosynth/BioPontis Alliance/Covance. She has presentated at several national and international conferences and currently serves on the Board of Directors for CureSearch for Children’s cancer.
Prathima is currently an independent consultant working with biotech companies. She has an eye for connecting innovation through structured alliances resulting in asset creation
Scientific Advisory Board
Prior to Fortebio, Dr. Witte was an early employee at Zyomyx and developed an advanced protein microarray instrument and consumable. Krista Witte is currently serving as advisor to several early stage companies including GlycoSelect and Digihelix.
Dr. Witte received her Ph.D in Chemistry from Scripps Research Institute in carbohydrate chemistry and was a Jane Coffin Childs Research Fellow at UC Berkeley in cancer research. In 2004 Krista was part of the founding team for Fortebio. She is an inventor on numerous patents for the label-free interferometry technology on which the company was based. Over her decade with Fortebio she managed teams of engineers and scientists to develop a successful product line of 7 instruments and 20+ biosensors. In 2012 Pall Corporation purchased Fortebio and she assumed the additional responsibility for the R&D of the Pall Genedisc QPCR line.
Dr. Krista Witte PhD.
Professor O'Kennedy has published extensively (170 peer-reviewed papers, 30 reviews, 25 book chapters, 1 book and has mentored 60 Ph.Ds to completion. He is a member of the Industrial Research and Commercialisation Committee at Enterprise Ireland, reviews for many journals and international scientific bodies, edits three journals, has patents and licensed technologies/reagents and works closely with Irish/ international companies. He has a major interest in innovative approaches to Healthcare and has received many awards for research (Biochemistry Medal of the RIA; Fujitsu Award for Innovation; Bioscience Lab of the Year, 2014) and teaching (President’s award, DCU; Outstanding Masters Programme Award, Graduate Ireland, 2011).
Professor O'Kennedy is a Professor of Biological Sciences and Scientific Director of the Biomedical Diagnostics Institute at Dublin City University (DCU). He is former Vice-President for Learning Innovation in DCU, currently President of the London International Youth Science Forum,Vice-President of the Institute of Biology of Ireland and represents Ireland and the Royal Irish Academy (RIA) on the Biosciences committee of the European Academies Science Advisory Council. He directs the Applied Biochemistry Research Group, internationally recognised for its expertise in antibody generation and immuno/ biosensor assay development.
In addition to her basic research interests, she has many links with pharmaceutical companies across the world because GlycoScience is a major area of specialised expertise required to ensure the safety and efficacy of biotherapeutic drugs, such as monoclonal antibodies for cancer and autoimmune disorders. In 2010 Prof Rudd was awarded the James Gregory Medal and an Agilent Thought Leader award and in 2012 she received a Waters Global Innovation award. In 2014 she was awarded an Honorary Doctorate at Gothenburg University, Sweden.
Prof. Richard O'Kennedy BSc, PhD., C.Biol., FSB., F.I.Biol.I., Dip. F.S., Dip. C.S.
Professor Rudd obtained a BSc in Chemistry at the University of London and a PhD in Glycobiology at the Open University, UK. She was a Founding Scientist of Wessex Biochemicals (later Sigma London), Visiting Research Associate at The Scripps Research Institute, CA, Visiting Professor of Biochemistry at Shanghai Medical University PRC, Visiting Scientist at Ben Gurion University of the Negev, Israel and an Erskine Visiting Fellow, Canterbury University, Christchurch, New Zealand. She is a Fellow of the Royal Society of Medicine, London, visiting Professor at St. George’s Hospital, London and an Adjunct Professor at North Eastern University, Boston, NUI Galway, Trinity College Dublin and at University College, Dublin. She is a VI at BTI, AStar, Singapore. In 2014 she was awarded an Honorary Doctorate at Gothenburg University, Sweden.
Prof. Rudd is a Research Professor of Glycobiology at University College Dublin. She heads the GlycoSciences Research Group at the National Institute for BioProcessing Research and Training in Ireland (NIBRT) where she is a PI and consultant. She has more than 280 scientific publications and has given over 350 lectures and seminars at international meetings. Before moving her group to Dublin in 2006, Professor Rudd was a member of the Oxford Glycobiology Institute for 25 years, where she was a Senior Research Fellow and a University Reader in Glycobiology at the University of Oxford.
Prof. Pauline Rudd BSc, LRIC, MA, PhD